End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy

End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy

BackgroundIn spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel therapies, little attention has been paid to latter stages of pati...

Descripció completa

Dades bibliogràfiques
Autors principals: Pierre Sesques, Lionel Karlin, Emmanuel Massy, Alizée Maarek, Guillaume Aussedat, Anne Lazareth, Camille Golfier, Fadhela Bouafia-Sauvy, Helene Lequeu, Dana Ghergus, Violaine Safar, Emmanuelle Ferrant, Emmanuel Bachy, Hervé Ghesquières, Cyrille B. Confavreux, Delphine Demangel, Emeline Perrial, Charles Dumontet
Format: Article
Idioma:English
Publicat: Frontiers Media S.A. 2024-10-01
Col·lecció:Frontiers in Oncology
Matèries:
myeloma
CD38 targeted therapies
end of life
management
curative and prophylactic therapies
Accés en línia:https://www.frontiersin.org/articles/10.3389/fonc.2024.1436587/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1436587/full

Ítems similars